Michael Demetriou
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$4.6MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $4.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 16, 2026 | NIH | STTR Phase II Maximizing GlyTR pan-cancer immunotherapy by enhancing target density | $1.0M | GLYTR THERAPEUTICS, INC. |
| Sep 10, 2025 | NIH | STTR Phase II Maximizing GlyTR pan-cancer immunotherapy by enhancing target density | $464K | GLYTR THERAPEUTICS, INC. |
| Aug 22, 2025 | NIH | STTR Phase II Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | $1.1M | GLYTR THERAPEUTICS, INC. |
| Aug 29, 2024 | NIH | STTR Phase II Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | $909K | GLYTR THERAPEUTICS, INC. |
| Sep 21, 2023 | NIH | STTR Phase I Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | $400K | GLYTR THERAPEUTICS, INC. with UNIVERSITY OF CALIFORNIA-IRVINE |
| Aug 1, 2021 | NIH | STTR Phase I Cancer Immunotherapy Targeting Tn Antigen | $398K | GLYTR THERAPEUTICS, INC. with UNIVERSITY OF CALIFORNIA-IRVINE |
| Aug 14, 2019 | NIH | STTR Phase I O-Glycan-dependent Immunotherapy for Cancer | $2K | GLYTR THERAPEUTICS, INC. |
| Sep 18, 2018 | NIH | STTR Phase I O-Glycan-dependent Immunotherapy for Cancer | $301K | GLYTR THERAPEUTICS, INC. with UNIVERSITY OF CALIFORNIA-IRVINE |
Peer ranks
Federal funding#315
Awards as PI#190
Patents#273
Companies
- GLYTR THERAPEUTICS, INC.Linked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.